key: cord-0930869-5ie7bog0
authors: Pinto, Dora; Sauer, Maximilian M.; Czudnochowski, Nadine; Low, Jun Siong; Tortorici, M. Alejandra; Housley, Michael P.; Noack, Julia; Walls, Alexandra C.; Bowen, John E.; Guarino, Barbara; Rosen, Laura E.; di Iulio, Julia; Jerak, Josipa; Kaiser, Hannah; Islam, Saiful; Jaconi, Stefano; Sprugasci, Nicole; Culap, Katja; Abdelnabi, Rana; Foo, Caroline; Coelmont, Lotte; Bartha, Istvan; Bianchi, Siro; Silacci-Fregni, Chiara; Bassi, Jessica; Marzi, Roberta; Vetti, Eneida; Cassotta, Antonino; Ceschi, Alessandro; Ferrari, Paolo; Cippà, Pietro E.; Giannini, Olivier; Ceruti, Samuele; Garzoni, Christian; Riva, Agostino; Benigni, Fabio; Cameroni, Elisabetta; Piccoli, Luca; Pizzuto, Matteo S.; Smithey, Megan; Hong, David; Telenti, Amalio; Lempp, Florian A.; Neyts, Johan; Havenar-Daughton, Colin; Lanzavecchia, Antonio; Sallusto, Federica; Snell, Gyorgy; Virgin, Herbert W.; Beltramello, Martina; Corti, Davide; Veesler, David
title: A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery
date: 2021-05-10
journal: bioRxiv
DOI: 10.1101/2021.05.09.442808
sha: 880fdabf5ef5549a11455970a6958a666e573ca6
doc_id: 930869
cord_uid: 5ie7bog0

The repeated spillovers of β-coronaviruses in humans along with the rapid emergence of SARS-CoV-2 escape variants highlight the need to develop broad coronavirus therapeutics and vaccines. Five monoclonal antibodies (mAbs) were isolated from COVID-19 convalescent individuals and found to cross-react with multiple β-coronavirus spike (S) glycoproteins by targeting the stem helix. One of these mAbs, S2P6, cross-reacts with more than twenty human and animal β-coronavirus S glycoproteins and broadly neutralizes SARS-CoV-2 and pseudotyped viruses from the sarbecovirus, merbecovirus and embecovirus subgenera. Structural and functional studies delineate the molecular basis of S2P6 cross-reactivity and broad neutralization and indicate that this mAb blocks viral entry by inhibiting membrane fusion. S2P6 protects hamsters challenged with SARS-CoV-2 (including the B.1.351 variant of concern) through direct viral neutralization and Fc-mediated effector functions. Serological and B cell repertoire analyses indicate that antibodies targeting the stem helix are found in some convalescent donors and vaccinees but are predominantly of narrow specificity. Germline reversion of the identified cross-reactive mAbs revealed that their unmutated ancestors are specific for the endemic OC43 or HKU1 viruses and acquired enhanced affinity and breadth through somatic mutations. These data demonstrate that conserved epitopes in the coronavirus fusion machinery can be targeted by protective antibodies and provide a framework for structure-guided design of pan-β-coronavirus vaccines eliciting broad protection.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative 62 agent of the coronavirus disease 2019 , emerged at the end of 2019 and seeded the 63 ongoing pandemic (1) . Coronaviruses are zoonotic pathogens found in avian and mammalian 64 reservoirs, including bats, palm civets, racoon dogs, pangolins and pigs to cite a few. Repeated surface plasmon resonance (SPR), we found that S2P6 Fab fragment had the highest affinity for 127 SARS-CoV-2 S and SARS-CoV S followed by MERS-CoV S and OC43 S with equilibrium 128 dissociation constants (KD) of 7, 7, 12 and 16 nM, respectively ( fig. S1F-G) . S2P6 also bound to 129 HKU1 S albeit with reduced affinity (KD ~120 nM) ( fig. S1F) . The recognition of prefusion SARS-130 CoV-2 S by this mAb is pH dependent with higher binding affinity at pH 7, relative to pH 5, in both 131 IgG and Fab formats ( fig. S1G) . Together, these data demonstrate the remarkable and efficient 132 cross-reactivity of S2P6 towards all human-infecting β-coronaviruses.

To evaluate the neutralization potency and breadth of S2P6, we investigated its ability to 134 inhibit entry of authentic SARS-CoV-2 into Vero-E6 cells in the presence or absence of the S-135 activating protease TMPRSS2. S2P6 completely neutralized infection of TMPRSS2-positive 136 Vero-E6 cells but was less effective in neutralizing infection of Vero-E6 cells (Fig. 1E) . Previous coronaviruses, and overlaps with the epitopes of B6 (Fig. 1I) and 28D9, two mAbs which were 155 previously identified following mouse immunization (12, 13). S2P6 bound efficiently to the stem 156 helix peptides of the five β-coronaviruses that infect humans (albeit with a faster off-rate for HKU1) 165 166 Fig. 2A, table S1 and fig S3) . 3D 196 classification of the cryo-EM data revealed incomplete Fab saturation ( fig. S3 ). Our cryo-EM 197 structure confirms that S2P6 recognizes the stem helix and suggests that the mAb disrupts its 198 quaternary structure, which is presumed to form a 3-helix bundle in prefusion SARS-CoV-2 S (3, 199 4, 12). To overcome the limited resolution of the stem helix/Fab interface in the cryoEM structure,

we determined a crystal structure of the S2P6 Fab in complex with the SARS-CoV-2 S stem helix 201 peptide (residues 1146-1159) at 2.67 Å resolution ( Fig. 2B-D, fig. S4A and table S2). The peptide 202 folds as an amphipathic ɑ-helix resolved for residues 1146 to 1159. S2P6 buries approximately 203 600 Å 2 upon binding to its epitope using shape-complementarity and hydrogen bonding involving 204 complementarity determining regions (CDR) H1-H3, L1 and L3. The light chain residues Y33, 205 Y92, G93, P96, P97 and F99 as well as heavy chain residues Y33, I50, H57, T58, S59, P101,

K102 and G103 form a deep groove in which the hydrophobic side of the stem helix docks via 207 residues F1148, L1152, Y1155 and F1156. Binding specificity is provided through backbone 208 hydrogen bonding of residues F1148SARS-CoV-2 and K1149SARS-CoV-2 with CDRH3 P101, side chain 209 hydrogen bonding of residues E1151SARS-CoV-2 with CDRL1 Y33 and CDRL3 S94, D1153SARS-CoV-2 210 with CDRH1 Y33 side chains as well as Y1155SARS-CoV-2 S with CDRH2 S59 through a water 211 molecule ( Fig. 2C-D) . The contribution of each epitope residue was validated by single . S5A ). Residue Y1155 is conservatively substituted 216 to F1238MERS-CoV or W1237/1240HKU1/OC43 and residue D1153 is conserved in MERS-CoV and OC43 but mutated to S1235 for HKU1 ( fig. S5B) . The residue scan and structural results suggest 218 that the reduced binding affinity of S2P6 for HKU1 S is (at least partially) due to the D1153 SARS-

CoV-2S1235HKU1 substitution which is expected to abrogate or dampen electrostatic interactions 220 with the CDRH1 Y33 side chain hydroxyl ( Fig. 2C-D) .

Although S2P6 and B6 recognize a similar epitope ( fig. S4B-C) , they bind with opposite 222 orientations of the heavy and light chains relative to the stem helix and the S2P6-bound structure 223 resolves 3 additional C-terminal peptide residues (1156-1159) compared to the B6-bound 224 structure (1147-1156) ( fig. S4B-C) . Superposition of both structures based on the stem helix 225 reveals that B6 CDRH2 would sterically clash with H1159SARS-CoV-2, putatively explaining the 226 broader cross-reactivity of S2P6 over B6 ( fig. S4B-C) .

To further validate our structural data, we carried out viral escape mutant selection in vitro 228 in the presence of S2P6 using a replication-competent VSV-SARS-CoV-2 S chimeric virus (23).

After two passages, virus neutralization by S2P6 was abrogated and deep sequencing revealed 

Only key interface residues and the S2P6 CDR loops are shown for clarity. Residues Q32 and 250 H57, that are mutated during affinity maturation of the S2P6 heavy chain, are colored blue.

Hydrogen bonds are indicated with dashed lines. Residues substituted in the escape mutants 252 isolated are underlined.

The S stem helix forms a 3-helix bundle in many prefusion cryoEM structures of SARS-

CoV-2 S and SARS-CoV S (3, 4, 11, (24) (25) (26) . In contrast, the S2P6/S2M11/SARS-CoV-2 S 257 cryoEM structure suggests that the quaternary organization of the stem is disrupted ( Fig. 2A) as 258 supported by the observation that S2P6 binds to the hydrophobic face of the stem helix which is 259 expected to be mostly buried through homo-oligomeric interactions in prefusion S, and that may 260 be only transiently available for Ab binding. Although we observed S2P6 binding to post-fusion 261 SARS-CoV-2 S ( fig. S1C) , the epitope recognized is buried at the interface with the other two 262 protomers of the rod-shaped trimer and is therefore not expected to be fully accessible ( fig. S4D) 

(12, 27-29). Based on these data, we hypothesized that S2P6 binding to S sterically interferes 264 with the conformational changes leading to membrane fusion, as observed for B6 (12) and 27D9 265 (13).

To validate the inferred mechanism of S2P6-mediated broad coronavirus neutralization,

we first showed that S2P6 binding did not block engagement of SARS-CoV-2 S by ACE2 using 268 ELISA, as expected based on the remote location of its epitope from the RBD (Fig. 3A) . S2P6, 269 however, blocked cell-cell fusion between Vero-E6 cells transfected with full-length SARS-CoV-2 270 S as effectively as the S2M11 mAb which locks SARS-CoV-2 S in the closed state (22) (Fig. 3B ).

We previously described mAbs targeting RBD antigenic site Ia (e.g. S2E12) and IIa (e.g. S2X259 

S2P6 binds to the hydrophobic core of the stem helix bundle and disrupts its quaternary structure.

S2P6 binding likely prevents S2 subunit refolding from the pre-to the post-fusion state and blocks 300 viral entry.

Fc-mediated effector functions can contribute to in vivo protection by promoting viral 304 clearance and anti-viral immune responses (32-35). We analyzed the ability of S2P6 to trigger 305 activation of FcgRIIa and FcgRIIIa, as well as to exert Fc effector functions in vitro. S2P6 promoted 306 moderate dose-dependent FcgRIIa and FcgRIIIa mediated signaling using a luciferase reporter 307 assay (Fig. 4A) . S2P6 promoted robust activation of Ab-dependent cell cytotoxicity (ADCC), to 308 levels comparable to those observed with the S309 mAb (21), following incubation of SARS-CoV-309 2 S expressing CHO-K1 target cells with human peripheral blood mononuclear cells (PBMCs) 310 (Fig. 4B) . S2P6 also triggered Ab-dependent cellular phagocytosis (ADCP) activity using Cell-

Trace-Violet-labelled PBMCs as phagocytic cells, and SARS-CoV-2 S expressing CHO (CHO-S) 312 as target cells (Fig. 4C) . Finally, S2P6 did not promote complement-dependent cytotoxicity (CDC) 313 ( Fig. 4D) indicating that S2P6 Fc-mediated effector functions, but not complement activation, 

Prophylactic administration of Hu-S2P6 at 20 mg/kg reduced replicating viral titers in the lungs 329 (but not RNA copy numbers) by ~1.5 order of magnitude relative to the control group, in line with 330 the strict conservation of the stem helix epitope in all VOC identified to date (Fig 4F) .

Collectively, these findings demonstrate that Abs targeting a highly conserved epitope in To understand how frequently stem helix-specific Abs are elicited, we performed 363 serological analysis using plasma samples from pre-pandemic, COVID-19 convalescent, and 364 COVID-19 vaccinated individuals ( Fig. 5A and fig. S6 ). We determined the titers of plasma IgG 365 binding to stem helix peptides of SARS-CoV-2/SARS-CoV (SARS-CoV/-2), OC43, MERS-CoV, 366 HKU1, HKU4 and HKU5. We did not observe plasma Abs binding to stem helix peptides in pre-367 pandemic samples, except for HKU1, probably reflecting prior infection with this virus in this 368 cohort. Conversely, stem helix-specific Abs were found at low frequency in individuals previously 369 infected with SARS-CoV-2 or receiving two doses of mRNA vaccines (Fig. 5A) . Overall, these S8 ). Most SARS-CoV-2 stem helix specific Abs were 379 found to be cross-reactive with OC43, consistent with the high sequence identity of the stem 380 helices of these two viruses (Fig. 1H) . Abs specific for the HKU1 S stem helix were found in some 381 individuals but they were not cross-reactive with other b-coronaviruses ( Fig. 5D and G) . This To define the ontogeny of the broadly reactive b-coronavirus mAbs described here, we 389 generated a panel of germline variants of S2P6, P34D10, P34E3 and P34G12 mAbs. Two out of 390 seven S2P6 heavy chain residues that are mutated relative to germline contribute to epitope 391 recognition (Q32 and H57) whereas none of the 5 light chain mutated residues participate in S 392 binding ( Fig. 2C-D) . To address the role of VH and VK somatic mutations we therefore generated 

(with approximately 1 order of magnitude higher EC50 compared to the mutated mAb) but not to 396 SARS-CoV/-2 or HKU1 peptides (Fig. 5H) . Somatic mutations in VH were sufficient for high avidity 397 binding to SARS-CoV/-2, whereas both VH and VK mutations were required for optimal binding 398 to HKU1. The presence of residue G103 in CDRH3 was found to be essential for binding to all b- 

The coronavirus S2 subunit (fusion machinery) contains several important antigenic sites, 429 including the fusion peptide and the heptad-repeat 2 regions, and is more conserved than the S1 

We also provide evidence that a S2 subunit-directed mAb protects hamsters from SARS- 

Protein expression and purification 577 SARS-CoV-2 S 2P, SARS-CoV S 2P, MERS-CoV S 2P, OC43 S, HKU1 S2P, and HKU4 S2P 578 ectodomains were produced as previously described (3, 11, 12, 59, 60) . SARS-CoV-2 S D614G, 579 used for production of SARS-CoV-2 postfusion, contains a mu-phosphatase signal peptide 580 beginning at 14Q, a mutated S1/S2 cleavage site (SGAR), and ends at residue K1211 followed by 

To perform pseudotype neutralization assays, VeroE6-TMPRSS2 cells were used for VSV-SARS- Primer Set 1 (NEB, E7600S) was used for library construction, with a total of 6 PCR cycles.

Libraries size was determined using the Agilent D1000 ScreenTape System (Agilent D1000 

CryoEM data processing

Movie frame alignment, estimation of the microscope contrast-transfer function parameters, 887 particle picking and extraction were carried out using Warp (75) . Particle images were extracted 888 with a box size of 1024 pixels 2 binned to 256 pixels 2 yielding a pixel size of 1.686 Å. Two rounds 889 of reference-free 2D classification were performed using cryoSPARC (76) to select well-defined 890 particle images. Subsequently, one round of 3D classification with 25 iterations was carried out 891 using Relion without imposing symmetry and using an initial ab initio model created in 892 cryoSPARC.

The best subclasses were combined and non-uniform refinement (NUR), defocus refinement (DR)

and NUR again performed in cryoSPARC. We then performed one round of global CTF 895 refinement of beam-tilt, trefoil and tetrafoil parameters followed by another refinement cycle of 896 NUR-DR-NUR. Selected particle images were then subjected to Bayesian polishing in Relion (77).

During this step the box and pixel size were changed to 426 pixels and 1.201 Å, respectively, 898 before performing another NUR-DR-NUR refinement cycle. We then performed one additional 

A pneumonia outbreak associated with a new coronavirus of 1076 probable bat origin

Structural insights into coronavirus entry

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Circulating SARS-CoV-2 spike N439K variants maintain fitness while 1095 evading antibody-mediated immunity

N-terminal 1101 domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive 1105 antibody escape

CoV-2 in an Immunocompromised Host

Identification of SARS-CoV-2 spike mutations 1116 that attenuate monoclonal and serum antibody neutralization

Escape from neutralizing 1122 antibodies by SARS-CoV-2 spike protein variants

Unexpected 1125 Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

Structural basis for broad coronavirus neutralization. bioRxiv (2020)

A 1134 conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by 1135 cross-reactive monoclonal antibodies

Structure and Function 1144 Analysis of an Antibody Recognizing All Influenza A Subtypes

Multiple roles for HIV broadly neutralizing 1146 antibodies

Chloroquine does not inhibit infection of 1149 human lung cells with SARS-CoV-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically 1153

A Multibasic Cleavage Site in the Spike 1155 Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Acquisition of complement resistance through incorporation of 1159

CD55/decay-accelerating factor into viral particles bearing baculovirus GP64

Cross-neutralization of SARS-CoV-2 by a human 1165 monoclonal SARS-CoV antibody

Ultrapotent human 1173 antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Neutralizing Antibody and Soluble ACE2 1179 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate

Cryo-electron microscopy 1182 structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state 1183 for receptor binding

Stabilized coronavirus spikes are 1186 resistant to conformational changes induced by receptor recognition or proteolysis

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal 1190 the dynamic receptor binding domains

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane 1193 fusion

Cryo-EM analysis of the post-fusion structure of the 1198 SARS-CoV spike glycoprotein

Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of 1203 different classes of antibodies

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-1212

Antibody potency, effector function, and combinations in protection and therapy 1218 for SARS-CoV-2 infection in vivo

Fc-optimized antibodies elicit CD8 1222 immunity to viral respiratory infection

1234 STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 1235 infected hamsters

A 1239 public antibody lineage that potently inhibits malaria infection through dual binding to the 1240 circumsporozoite protein

Clonal dissection of the 1242 human memory B-cell repertoire following infection and vaccination

Identification of an immunodominant linear neutralization domain on the S2 portion 1246 of the murine coronavirus spike glycoprotein and evidence that it forms part of complex 1247 tridimensional structure

Identification of an antigenic determinant on the S2 domain of the severe 1250 acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing 1251 antibodies

Two linear epitopes on the SARS-CoV-2 spike protein that elicit 1256 neutralising antibodies in COVID-19 patients

Human monoclonal 1258 antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike 1259 protein are more broadly neutralizing

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the 1263 newly-emerged SARS-CoV-2

Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer

A protective broadly cross-reactive human antibody defines a conserved site of 1272 vulnerability on beta-coronavirus spikes. bioRxivorg (2021)

A neutralizing antibody selected from

Broadly neutralizing hemagglutinin stalk-1281 specific antibodies require FcγR interactions for protection against influenza virus in vivo

Heterosubtypic neutralizing antibodies are produced by 1286 individuals immunized with a seasonal influenza vaccine

De novo protein design enables the precise 1293 induction of RSV-neutralizing antibodies

Computation-1297 guided backbone grafting of a discontinuous motif onto a protein scaffold

Proof of principle 1303 for epitope-focused vaccine design

Elicitation of Potent 1310

Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-1311

Elicitation of broadly protective sarbecovirus immunity by receptor-1319 binding domain nanoparticle vaccines. bioRxivorg (2021)

Quadrivalent influenza nanoparticle vaccines induce broad protection

Self-assembling influenza nanoparticle vaccines 1328 elicit broadly neutralizing H1N1 antibodies

Mosaic nanoparticle display of diverse 1334 influenza virus hemagglutinins elicits broad B cell responses

Induction of Potent Neutralizing Antibody Responses by a 1340

Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus

Structural basis for broad sarbecovirus 1349 neutralization by a human monoclonal antibody. bioRxivorg (2021)

Structural basis for human coronavirus attachment to 1353 sialic acid receptors

Structures of MERS-CoV spike glycoprotein in complex with sialoside 1356 attachment receptors

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape

Trimmomatic: a flexible trimmer for Illumina sequence 1367 data

Aligning sequence reads, clone sequences and assembly contigs with

LoFreq: a sequence-quality aware, ultra-sensitive 1372 variant caller for uncovering cell-population heterogeneity from high-throughput sequencing 1373 datasets

A program for annotating and predicting the effects of single nucleotide 1376 polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain

Mosdepth: quick coverage calculation for genomes and 1379 exomes

Twelve years of SAMtools and BCFtools

MultiQC: summarize analysis results for 1384 multiple tools and samples in a single report

Nextflow enables reproducible computational workflows

Bioconda: sustainable and comprehensive software distribution 1390 for the life sciences

Features and development of Coot

ISOLDE: a physically realistic environment for model building into low-resolution 1394 electron-density maps

REFMAC5 for the refinement of macromolecular crystal 1397 structures

Automated molecular microscopy: the new Leginon system

Real-time cryo-electron microscopy data preprocessing with Warp

cryoSPARC: algorithms for rapid 1404 unsupervised cryo-EM structure determination

A Bayesian approach to beam-induced motion 1406 correction in cryo-EM single-particle analysis

High-resolution noise substitution to measure overfitting and validate resolution 1409 in 3D structure determination by single particle electron cryomicroscopy

UCSF Chimera--a visualization system for exploratory research and analysis

A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT 1415 ENDPOINTS12

AncesTree: An interactive 1417 immunoglobulin lineage tree visualizer

We thank Jay C. Nix for x-ray data collection, and Tristan I. Croll for assistance in refinement of 473 the crystal structure. Thanks to Ann Arvin for her insightful comments. We thank Marcel Meury